ASH 2023 Post Conference Perspectives: Highlights in Multiple Myeloma
Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.
The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.
The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.
A key opinion leader explores the integration of bispecifics into MM therapy regimens.
Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.
Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
3
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5